Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

by Barro, C., Benkert, P., Chung, L., Daizadeh, N., Godin, J., Havari, E., Jacobs, A., Kaiser, C., Kappos, L., Kuhle, J., Leppert, D., Maceski, A., Michalak, Z., Mitchell, C.P, Rӧsch, N., Samad, T.A, Shankara, S., Sormani, M.P
Published 2022

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

by Battaglia, M.A, Brichetto, G., Caleri, F., Callari, G., Carmisciano, L., Clerico, M., Cocco, E., Cordera, S., Cordioli, C., CovaXiMS study group, Di Sapio, A., Ferrò, M.T, Franciotta, D., Frau, J., Gandoglia, I., Gazzola, P., Inglese, M., Iodice, R., Landi, D., Lapucci, C., Laroni, A., Liberatore, G., Mannironi, A., Marinelli, F., Pasquali, L., Perego, G., Pizzorno, M., Repice, A.M, Salvetti, M., Schiavetti, I., Serrati, C., Signoriello, E., Sormani, M.P, Stromillo, M.L, Tassinari, T., Uccelli, A., Ulivelli, M., Visconti, V.
Published 2022